Association between ABO blood groups and gastric cancer outcomes: a Kaplan-Meier-derived patient data meta-analysis.

IF 2.1 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarkers in medicine Pub Date : 2026-05-01 Epub Date: 2026-06-11 DOI:10.1080/17520363.2026.2678430

Francisco Cezar Aquino de Moraes, Gustavo Tadeu Freitas Uchôa Matheus, Luis Henrique Rios Moreira Rego, Felipe Alves de Paiva, Rommel Mario Rodriguez Burbano, Mario Hiroyuki Hirata

{"title":"Association between ABO blood groups and gastric cancer outcomes: a Kaplan-Meier-derived patient data meta-analysis.","authors":"Francisco Cezar Aquino de Moraes, Gustavo Tadeu Freitas Uchôa Matheus, Luis Henrique Rios Moreira Rego, Felipe Alves de Paiva, Rommel Mario Rodriguez Burbano, Mario Hiroyuki Hirata","doi":"10.1080/17520363.2026.2678430","DOIUrl":null,"url":null,"abstract":"Background: Gastric cancer (GC) remains the fifth most common and lethal cancer worldwide, often diagnosed at advanced stages, with limited treatment options and poor survival. Beyond established risk factors, the ABO blood group system has been suggested as a potential prognostic factor, but evidence remains inconclusive.Methods: Medline, Scopus, and Web of Science were searched to 27 July 2025, for studies including GC patients with reported overall survival (OS) stratified by blood types O, A, B, and AB. Kaplan-Meier curves from eligible studies were digitized to reconstruct individual patient data, which were pooled to estimate median OS and hazard ratios (HR) using Cox regression.Results: Seven studies comprising 8,726 GC patients were included (O: 3,693; A: 946; B: 605; AB: 315). Median OS was highest for type O (85.1 months, 95% CI 77.5-86.4) and AB (78.2 months, 95% CI 73.9-NA), and lowest for type A (20.0 months, 95% CI 17.9-21.9) and B (35.5 months, 95% CI 27.9-78.5). Compared with non-O, type O had a significantly better prognosis (HR 0.63; p < 0.0001). Type A (HR 1.85; p < 0.0001) and type B (HR 1.20; p = 0.0018) were associated with worse survival, while type AB showed a favorable prognosis compared to non-AB (HR 0.83; p = 0.039).Conclusion: ABO blood group is a significant prognostic factor in GC, with types A and B linked to poorer survival.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"461-470"},"PeriodicalIF":2.1000,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13285578/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2026.2678430","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/11 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Gastric cancer (GC) remains the fifth most common and lethal cancer worldwide, often diagnosed at advanced stages, with limited treatment options and poor survival. Beyond established risk factors, the ABO blood group system has been suggested as a potential prognostic factor, but evidence remains inconclusive.

Methods: Medline, Scopus, and Web of Science were searched to 27 July 2025, for studies including GC patients with reported overall survival (OS) stratified by blood types O, A, B, and AB. Kaplan-Meier curves from eligible studies were digitized to reconstruct individual patient data, which were pooled to estimate median OS and hazard ratios (HR) using Cox regression.

Results: Seven studies comprising 8,726 GC patients were included (O: 3,693; A: 946; B: 605; AB: 315). Median OS was highest for type O (85.1 months, 95% CI 77.5-86.4) and AB (78.2 months, 95% CI 73.9-NA), and lowest for type A (20.0 months, 95% CI 17.9-21.9) and B (35.5 months, 95% CI 27.9-78.5). Compared with non-O, type O had a significantly better prognosis (HR 0.63; p < 0.0001). Type A (HR 1.85; p < 0.0001) and type B (HR 1.20; p = 0.0018) were associated with worse survival, while type AB showed a favorable prognosis compared to non-AB (HR 0.83; p = 0.039).

Conclusion: ABO blood group is a significant prognostic factor in GC, with types A and B linked to poorer survival.

查看原文本刊更多论文

ABO血型与胃癌结局之间的关系：kaplan - meier衍生的患者数据荟萃分析

背景：胃癌（GC）仍然是世界上第五大最常见和最致命的癌症，通常在晚期诊断，治疗选择有限，生存率低。除了确定的危险因素外，ABO血型系统被认为是一个潜在的预后因素，但证据仍然不确定。方法：检索Medline、Scopus和Web of Science，检索到2025年7月27日，包括按O型、A型、B型和AB型血分层报告总生存期（OS）的GC患者的研究。将符合条件的研究中的Kaplan-Meier曲线数字化，重建个体患者数据，并使用Cox回归估计中位OS和风险比（HR）。结果：纳入了7项研究，包括8,726例胃癌患者（O: 3,693; A: 946; B: 605; AB: 315）。O型（85.1个月，95% CI 77.5-86.4）和AB型（78.2个月，95% CI 73.9-NA）的中位OS最高，A型（20.0个月，95% CI 17.9-21.9）和B型（35.5个月，95% CI 27.9-78.5）的中位OS最低。与非O型患者相比，O型患者预后较好（HR 0.63, p = 0.0018），而AB型患者预后较好（HR 0.83, p = 0.039）。结论：ABO血型是胃癌的重要预后因素，a型和B型与较差的生存相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.